全文获取类型
收费全文 | 10536篇 |
免费 | 553篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 275篇 |
妇产科学 | 153篇 |
基础医学 | 1318篇 |
口腔科学 | 222篇 |
临床医学 | 702篇 |
内科学 | 2766篇 |
皮肤病学 | 208篇 |
神经病学 | 1135篇 |
特种医学 | 354篇 |
外科学 | 1714篇 |
综合类 | 58篇 |
一般理论 | 1篇 |
预防医学 | 260篇 |
眼科学 | 332篇 |
药学 | 500篇 |
中国医学 | 19篇 |
肿瘤学 | 1044篇 |
出版年
2023年 | 81篇 |
2022年 | 58篇 |
2021年 | 302篇 |
2020年 | 177篇 |
2019年 | 249篇 |
2018年 | 340篇 |
2017年 | 228篇 |
2016年 | 239篇 |
2015年 | 237篇 |
2014年 | 345篇 |
2013年 | 413篇 |
2012年 | 628篇 |
2011年 | 624篇 |
2010年 | 329篇 |
2009年 | 269篇 |
2008年 | 503篇 |
2007年 | 509篇 |
2006年 | 465篇 |
2005年 | 549篇 |
2004年 | 480篇 |
2003年 | 422篇 |
2002年 | 389篇 |
2001年 | 247篇 |
2000年 | 253篇 |
1999年 | 204篇 |
1998年 | 94篇 |
1997年 | 75篇 |
1996年 | 54篇 |
1995年 | 62篇 |
1994年 | 69篇 |
1993年 | 47篇 |
1992年 | 187篇 |
1991年 | 178篇 |
1990年 | 157篇 |
1989年 | 172篇 |
1988年 | 159篇 |
1987年 | 120篇 |
1986年 | 115篇 |
1985年 | 129篇 |
1984年 | 101篇 |
1983年 | 88篇 |
1979年 | 77篇 |
1977年 | 49篇 |
1976年 | 45篇 |
1974年 | 48篇 |
1973年 | 59篇 |
1972年 | 52篇 |
1970年 | 57篇 |
1969年 | 52篇 |
1968年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
目的分析中性粒细胞与淋巴细胞比值(NLR)对急性腔隙性脑梗死患者病情进展的预测价值。方法根据病情进展与否将2012年2月~2017年1月收治的230例急性腔隙性脑梗死患者分为进展组(40例)与非进展组(190例),记录各组中性粒细胞绝对值、淋巴细胞绝对值等指标,计算NLR。受试者工作特征(ROC)曲线分析NLR等对急性腔隙性脑梗死患者病情进展预测的特异度、敏感度,Pearson相关性分析NLR等指标与mRS评分的关系。结果进展组NLR、白细胞计数、中性粒细胞绝对值均显著高于非进展组(P 0. 05);淋巴细胞绝对值显著低于非进展组(P 0. 05)。NLR对进展性腔隙性脑梗死(PLI)预测曲线下面积(AUC)为0. 800,最佳临界值3. 25,敏感度85. 06%,特异度70. 68%;白细胞计数、中性粒细胞绝对值、淋巴细胞绝对值对PLI预测AUC分别为0. 650、0. 745、0. 615。进展组预后良好率显著低于非进展组(P 0. 05)。NLR、中性粒细胞绝对值、白细胞计数与mRS评分正相关(P 0. 05)。结论 NLR值对急性腔隙性脑梗死患者病情进展有一定的预测价值,有可能作为患者预后评估的有效指标。 相似文献
4.
Yu Akazawa Yuki Saito Toshiaki Yoshikawa Keigo Saito Kazuto Nosaka Manami Shimomura Shoichi Mizuno Yasunari Nakamoto Tetsuya Nakatsura 《Cancer science》2020,111(8):2736-2746
Lung cancer is the leading cause of cancer‐related deaths worldwide. Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) often have good clinical activity against non–small cell lung cancer (NSCLC) with activating EGFR mutations. Osimertinib, which is a third‐generation EGFR‐TKI, has a clinical effect even on NSCLC harboring the threonine to methionine change at codon 790 of EGFR (EGFR T790M) mutation that causes TKI resistance. However, most NSCLC patients develop acquired resistance to osimertinib within approximately 1 year, and 40% of these patients have the EGFR T790M and cysteine to serine change at codon 797 (C797S) mutations. Therefore, there is an urgent need for the development of novel treatment strategies for NSCLC patients with the EGFR T790M/C797S mutation. In this study, we identified the EGFR T790M/C797S mutation‐derived peptide (790‐799) (MQLMPFGSLL) that binds the human leukocyte antigen (HLA)‐A*02:01, and successfully established EGFR T790M/C797S‐peptide‐specific CTL clones from human PBMC of HLA‐A2 healthy donors. One established CTL clone demonstrated adequate cytotoxicity against T2 cells pulsed with the EGFR T790M/C797S peptide. This CTL clone also had high reactivity against cancer cells that expressed an endogenous EGFR T790M/C797S peptide using an interferon‐γ (IFN‐γ) enzyme‐linked immunospot (ELISPOT) assay. In addition, we demonstrated using a mouse model that EGFR T790M/C797S peptide‐specific CTL were induced by EGFR T790M/C797S peptide vaccine in vivo. These findings suggest that an immunotherapy targeting a neoantigen derived from EGFR T790M/C797S mutation could be a useful novel therapeutic strategy for NSCLC patients with EGFR‐TKI resistance, especially those resistant to osimertinib. 相似文献
5.
6.
Shota Nukaga Takuya Mori Yoshihiro Miyagawa Rina FujiwaraTani Takamitsu Sasaki Kiyomu Fujii Shiori Mori Kei Goto Shingo Kishi Chie Nakashima Hitoshi Ohmori Isao Kawahara Yi Luo Hiroki Kuniyasu 《Cancer science》2020,111(12):4605
Cancer‐derived myocardial damage is an important cause of death in cancer patients. However, the development of dietary interventions for treating such damage has not been advanced. Here, we investigated the effect of dietary intervention with lauric acid (LAA) and glucose, which was effective against skeletal muscle sarcopenia in a mouse cachexia model, on myocardial damage. Treatment of H9c2 rat cardiomyoblasts with lauric acid promoted mitochondrial respiration and increased ATP production by Seahorse flux analysis, but did not increase oxidative stress. Glycolysis was also promoted by LAA. In contrast, mitochondrial respiration and ATP production were suppressed, and oxidative stress was increased in an in vitro cachexia model in which cardiomyoblasts were treated with mouse cachexia ascites. Ascites‐treated H9c2 cells with concurrent treatment with LAA and high glucose showed that mitochondrial respiration and glycolysis were promoted more than that of the control, and ATP was restored to the level of the control. Oxidative stress was also reduced by the combined treatment. In the mouse cachexia model, myocardiac atrophy and decreased levels of a marker of muscle maturity, SDS‐soluble MYL1, were observed. When LAA in CE‐2 diet was orally administered alone, no significant rescue was observed in the cancer‐derived myocardial disorder. In contrast, combined oral administration of LAA and glucose recovered myocardial atrophy and MYL1 to levels observed in the control without increase in the cancer weight. Therefore, it is suggested that dietary intervention using a combination of LAA and glucose for cancer cachexia might improve cancer‐derived myocardial damage. 相似文献
7.
Tatsuaki Takeda Hiromasa Yamamoto Ken Suzawa Shuta Tomida Shunsaku Miyauchi Kota Araki Kentaro Nakata Akihiro Miura Kei Namba Kazuhiko Shien Junichi Soh Tadahiko Shien Yoshihisa Kitamura Toshiaki Sendo Shinichi Toyooka 《Cancer science》2020,111(3):849-856
Molecular‐targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2‐positive breast cancer. However, acquired resistance of various cancers to molecular‐targeted drugs is an issue of clinical concern, and emergence of resistance to neratinib is also considered inevitable. In this study, we established various types of neratinib‐resistant cell lines from HER2‐amplified breast and lung cancer cell lines using several drug exposure conditions. We analyzed the mechanisms of emergence of the resistance in these cell lines and explored effective strategies to overcome the resistance. Our results revealed that amplification of YES1, which is a member of the SRC family, was amplified in two neratinib‐resistant breast cancer cell lines and one lung cancer cell line. Knockdown of YES1 by siRNA and pharmacological inhibition of YES1 by dasatinib restored the sensitivity of the YES1‐amplified cell lines to neratinib in vitro. Combined treatment with dasatinib and neratinib inhibited tumor growth in vivo. This combination also induced downregulation of signaling molecules such as HER2, AKT and MAPK. Our current results indicate that YES1 plays an important role in the emergence of resistance to HER2‐targeted drugs, and that dasatinib enables such acquired resistance to neratinib to be overcome. 相似文献
8.
9.
10.